BACKGROUND Patients with left ventricular (LV) systolic dysfunction, coronary artery disease (CAD), and angina are often thought to have a worse prognosis and a greater prognostic benefit from coronary artery bypass graft (CABG) surgery than those without angina.
C oronary artery bypass grafting (CABG) is recommended in patients with angina (1), coronary artery disease (CAD), and left ventricular (LV) systolic dysfunction (2, 3) ; however, compelling evidence that the presence or absence of angina should guide decisions about revascularization is lacking (4) . Tests of myocardial viability or stress-induced ischemia have failed so far to identify a subset of patients with heart failure who have more to gain from CABG than from medical therapy alone in randomized controlled trials (5, 6) .
Clinical guidelines identify angina as an important consideration for the decision of whether patients with heart failure and reduced LV function should have CABG (7) . Angina pectoris signals the presence of viable myocardium that is prone to ischemia and at risk of infarction and may therefore confer an adverse outcome (8) . Patients with heart failure and CAD who do not have angina might have less jeopardized myocardium at risk of ischemia, which might indicate a better prognosis, or have cardiac denervation that renders myocardial ischemia silent or have a substantial volume of myocardium affected by hibernation or replaced by scar, which could signal an adverse prognosis (9, 10) . Surprisingly, information on the prognostic significance of angina in patients with heart failure who are known to have CAD has not been reported. Accordingly, we conducted an analysis of the STICH (Surgical Treatment for Ischemic Heart Failure) trial data to address 3 questions. 1) Does the presence of angina influence outcomes in patients with heart failure and CAD managed without resort to revascularization? 2) Does angina identify patients who will experience a greater survival benefit from CABG? 3)
Does CABG improve angina in this population?
METHODS STUDY POPULATION. The rationale and design of the STICH trial were published previously (11) . STICH was a prospective, multicenter, randomized trial sponsored by the National Heart, Lung, and Blood Institute that recruited patients with CAD and an LV ejection fraction of 35% or less between 2002 and 2007 (NCT00023595) (4) . For the present study, 1,212 participants who were enrolled in the surgical revascularization hypothesis part of the trial were included. This part of the STICH trial assessed whether CABG combined with optimal medical therapy improved survival compared with optimal medical therapy alone. The inclusion and exclusion criteria and the requirements for ensuring high-quality surgical revascularization have been described previously (12) . The National Heart, Lung, and Blood Institute and the ethics committee at each recruiting institution approved the study protocol.
All patients provided written informed consent. All authors have read and agreed to the paper as written.
STUDY OUTCOMES. A blinded clinical events committee adjudicated all deaths using pre-specified criteria (4, 11 The STICH Angina Analysis For each model, candidate variables were prespecified using either clinical experience or previously reported risk factors (4, 5, 14) . The primary analysis was on the basis of the intention-to-treat principle. We repeated the analyses according to the treatments actually received (rather than assigned) to ascertain the influence of crossover outcomes. Among patients assigned to medical therapy, all-cause mortality was similar in patients with and without angina (hazard ratio: 1.05; 95% confidence interval: 0.79 to 1.38). Figure 2) ; however, the interaction between the presence of angina and the effect of CABG versus medical therapy on survival was not significant (p ¼ 0.14). The composite of allcause mortality or hospitalizations was reduced to a similar extent in patients assigned to CABG whether they had angina or not (HR: 0.78; 95% CI: 0.66 to 0.93, and HR: 0.80; 95% CI: 0.64 to 1.00, respectively) ( Table 3 ). When crossovers from one treatment arm to another were considered, mortality was lower in patients with and without angina if they had CABG (HR: 0.67; 95% CI: 0.53 to 0.85, and HR: 0.63; 95% CI: 0.47 to 0.88, respectively) (Online Figure 1 , Online Table 4 ). Data for other cardiovascular endpoints are presented in Online Table 5 . Table 3) . Years OR ¼ odds ratio; other abbreviations as in Tables 1 and 2 . The STICH Angina Analysis
DISCUSSION

